TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Arovella Therapeutics Limited ( (AU:ALA) ) is now available.
Arovella Therapeutics Ltd has entered into a Sponsored Research Agreement with the University of North Carolina to enhance its research capabilities for IL-12-TM and solid tumor programs. This collaboration with Professor Gianpietro Dotti’s research group aims to strengthen Arovella’s position in the biotechnology sector by advancing its CAR-iNKT cell programs, potentially improving treatment options for solid tumors.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company specializing in the development of invariant Natural Killer T (iNKT) cell therapy platforms to treat blood cancers and solid tumors. Their lead product, ALA-101, involves CAR19-iNKT cells targeting CD19 and CD1d antigens, and the company is expanding into solid tumor treatments with CLDN18.2-targeting technology and IL-12-TM technology.
YTD Price Performance: -35.29%
Average Trading Volume: 1,538,648
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$117.1M
See more data about ALA stock on TipRanks’ Stock Analysis page.